Cargando…

Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells

The prognosis for patients with relapsed or refractory high-risk neuroblastoma remains dismal and novel therapeutic options are urgently needed. The RIST treatment protocol has a multimodal metronomic therapy design combining molecular-targeted drugs (Rapamycin and Dasatinib) with chemotherapy backb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waetzig, Rebecca, Matthes, Marie, Leister, Johannes, Penkivech, Gina, Heise, Tilman, Corbacioglu, Selim, Sommer, Gunhild
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738968/ https://www.ncbi.nlm.nih.gov/pubmed/33390782 http://dx.doi.org/10.7150/ijms.48393

Ejemplares similares

Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model
por: Kaess, Carina, et al.
Publicado: (2023)

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
por: Park, Seohyun, et al.
Publicado: (2016)

Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
por: Amin, Anubhav G., et al.
Publicado: (2021)

The RIST project at ISIS
por: Bennett, J R J, et al.
Publicado: (1994)

Progress of the RIST project
por: Bennett, J R J, et al.
Publicado: (1996)

Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
por: Francipane, Maria Giovanna, et al.
Publicado: (2013)

Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors †
por: Shaik, Althaf, et al.
Publicado: (2018)

Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes
por: Xu, Song, et al.
Publicado: (2017)

While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts
por: Leontieva, Olga V., et al.
Publicado: (2017)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
por: Murray, James T., et al.
Publicado: (2018)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA
por: Shappley, Rebekah K. H., et al.
Publicado: (2014)

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)

The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling
por: Yoon, Mee-Sup
Publicado: (2017)

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
por: Lawrence, Jessica, et al.
Publicado: (2018)

Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
por: Querfurth, Henry, et al.
Publicado: (2021)

Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
por: Hu, Yi, et al.
Publicado: (2020)

Revisiting the Rist diagram for predicting operating conditions in blast furnaces with multiple injections
por: Bailera, Manuel, et al.
Publicado: (2021)

GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
por: Scott, Kenneth L., et al.
Publicado: (2009)

Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
por: Seto, Belinda
Publicado: (2012)

mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain
por: Yang, Haijuan, et al.
Publicado: (2013)

Brain size is controlled by the mammalian target of rapamycin (mTOR) in mice
por: Kim, Woo-Yang
Publicado: (2015)

The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment
por: Maiese, Kenneth
Publicado: (2020)

Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy
por: Zhao, Wei, et al.
Publicado: (2023)

Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer
por: Cao, Guo-dong, et al.
Publicado: (2016)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

RNA-Binding Protein La Mediates TGFβ-Induced Epithelial to Mesenchymal Transition and Cancer Stem Cell Properties
por: Heise, Tilman, et al.
Publicado: (2021)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR)
por: Jimenez, Rosa H., et al.
Publicado: (2010)

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)

The mTOR Inhibitor Rapamycin Has Limited Acute Anticonvulsant Effects in Mice
por: Hartman, Adam L., et al.
Publicado: (2012)

The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
por: Soliman, Ghada A.
Publicado: (2013)

Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR
por: Zhang, Xiaoli, et al.
Publicado: (2019)

mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in Neurodegeneration
por: Norwitz, Nicholas G., et al.
Publicado: (2020)

Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy
por: Wu, Minmin, et al.
Publicado: (2020)

Temporal changes in mammalian target of rapamycin (mTOR) and phosphorylated-mTOR expressions in the hippocampal CA1 region of rat with vascular dementia
por: Park, Jin-A, et al.
Publicado: (2017)

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
por: Chan, S
Publicado: (2004)

New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
por: Carraway, Hetty, et al.
Publicado: (2004)

Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin
por: Saito, Keita, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_v0k3v5ufi83u5cqu6fbdl88kde